A. S. Martin

Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis

S. Chanock, H. Deeg, Jia Liu, 2022, Nature Communications.

Optimal donor for African Americans with hematologic malignancy: HLA-haploidentical relative or umbilical cord blood transplant.

K. Ballen, O. Ringdén, D. Rizzieri, 2020, Biology of Blood and Marrow Transplantation.

The effect of G-CSF use on hospital length of stay after an allogeneic hematopoietic cell transplantation: a retrospective multicenter cohort study.

M. Eapen, S. Chhabra, G. George, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort Study

V. Brown, M. Krem, S. Gadalla, 2022, Transplantation and Cellular Therapy.

Prior Gemtuzumab Ozogamicin Exposure in Adults With Acute Myeloid Leukemia Does Not Increase Hepatic Veno-occlusive Disease Risk After Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis.

W. Saber, V. Ho, F. Loberiza, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Decrease post-transplant relapse using donor-derived expanded NK-cells

K. Rezvani, G. Behbehani, E. Shpall, 2021, Leukemia.

Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide

Shannon R. McCurdy, M. Perales, M. Horowitz, 2016 .

T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes

M. Pasquini, J. Wingard, K. Ballen, 2018, Blood.

Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls

E. Shpall, M. Pasquini, Q. Bashir, 2019, Blood.